[
  {
    "ts": null,
    "headline": "Pfizer Stock Surges After Company Makes a Deal With President Trump",
    "summary": "Pfizer shares jumped 6.83% Tuesday after President Trump said the drugmaker would offer some of its drugs on a new direct-to-consumer website and would introduce new drugs to the U.S. market at reduced prices.",
    "url": "https://finnhub.io/api/news?id=7d92d7b7741021982a383fc4de2cc1217781dc0f90208cc0b66ef8179cf823cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759266883,
      "headline": "Pfizer Stock Surges After Company Makes a Deal With President Trump",
      "id": 136943999,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Pfizer shares jumped 6.83% Tuesday after President Trump said the drugmaker would offer some of its drugs on a new direct-to-consumer website and would introduce new drugs to the U.S. market at reduced prices.",
      "url": "https://finnhub.io/api/news?id=7d92d7b7741021982a383fc4de2cc1217781dc0f90208cc0b66ef8179cf823cb"
    }
  },
  {
    "ts": null,
    "headline": "Drug Manufacturers Help Push US Equity Indexes Higher While Government Shutdown Looms",
    "summary": "US equity indexes rose at the close on Tuesday as gains in healthcare stocks helped offset declines",
    "url": "https://finnhub.io/api/news?id=99313131e7cf3d82c030e71c9dcfc47a822c2fd036838e289d7fe78aa2289d52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759266345,
      "headline": "Drug Manufacturers Help Push US Equity Indexes Higher While Government Shutdown Looms",
      "id": 136944051,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "US equity indexes rose at the close on Tuesday as gains in healthcare stocks helped offset declines",
      "url": "https://finnhub.io/api/news?id=99313131e7cf3d82c030e71c9dcfc47a822c2fd036838e289d7fe78aa2289d52"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Post Late Rally After Trump Strikes Deal With Pfizer",
    "summary": "Gains in pharmaceutical stocks lifted indexes, despite the threat of an imminent government shutdown.",
    "url": "https://finnhub.io/api/news?id=58165ca615c2838efee6978fd1fdad750dc17a02d72693011af8e05ce8466ab1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759264680,
      "headline": "Stocks Post Late Rally After Trump Strikes Deal With Pfizer",
      "id": 136944003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Gains in pharmaceutical stocks lifted indexes, despite the threat of an imminent government shutdown.",
      "url": "https://finnhub.io/api/news?id=58165ca615c2838efee6978fd1fdad750dc17a02d72693011af8e05ce8466ab1"
    }
  },
  {
    "ts": null,
    "headline": "NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results",
    "summary": "PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2025. Operational Highlights of the 2025 Half Year Period and To Date Expanding c",
    "url": "https://finnhub.io/api/news?id=975c909e92c75313aec87e6409bd6f0e5e24c92aa7da04b33109b87830905b48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759263300,
      "headline": "NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results",
      "id": 136944053,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2025. Operational Highlights of the 2025 Half Year Period and To Date Expanding c",
      "url": "https://finnhub.io/api/news?id=975c909e92c75313aec87e6409bd6f0e5e24c92aa7da04b33109b87830905b48"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Johnson & Johnson: “It’s Differentiating Itself From the Pack”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer shared his take on. Cramer appreciated the company’s research and products during the episode, as he commented: “Even though it’s been a terrible year for healthcare stocks, there are still a handful of real winners like Johnson and Johnson, up more than 24% year […]",
    "url": "https://finnhub.io/api/news?id=2c0589c13281aecc86797e78718be79c513b7acd35587533fe9a30a74bd7773d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759255474,
      "headline": "Jim Cramer on Johnson & Johnson: “It’s Differentiating Itself From the Pack”",
      "id": 136944054,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer shared his take on. Cramer appreciated the company’s research and products during the episode, as he commented: “Even though it’s been a terrible year for healthcare stocks, there are still a handful of real winners like Johnson and Johnson, up more than 24% year […]",
      "url": "https://finnhub.io/api/news?id=2c0589c13281aecc86797e78718be79c513b7acd35587533fe9a30a74bd7773d"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Growth Catalysts Incoming",
    "summary": "Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous blockbuster drug. Read why REGN is a Buy.",
    "url": "https://finnhub.io/api/news?id=bb66c6e3504758db315ceacc9eb99a4641b7f297c884b7e7544ade750efc5d34",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759249535,
      "headline": "Regeneron: Growth Catalysts Incoming",
      "id": 136939389,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962383/image_1386962383.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous blockbuster drug. Read why REGN is a Buy.",
      "url": "https://finnhub.io/api/news?id=bb66c6e3504758db315ceacc9eb99a4641b7f297c884b7e7544ade750efc5d34"
    }
  },
  {
    "ts": null,
    "headline": "Prudential Financial Elects Joseph Wolk to Board of Directors",
    "summary": "NEWARK, N.J., September 30, 2025--Prudential Financial, Inc. (NYSE: PRU) announced today that Joseph Wolk has been elected to the Board of Directors as an independent director.",
    "url": "https://finnhub.io/api/news?id=eed6d73b5280f091e39f92be7f6499a68a026ed82de2193fd1d572cd274c4ee0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759235700,
      "headline": "Prudential Financial Elects Joseph Wolk to Board of Directors",
      "id": 136936096,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEWARK, N.J., September 30, 2025--Prudential Financial, Inc. (NYSE: PRU) announced today that Joseph Wolk has been elected to the Board of Directors as an independent director.",
      "url": "https://finnhub.io/api/news?id=eed6d73b5280f091e39f92be7f6499a68a026ed82de2193fd1d572cd274c4ee0"
    }
  },
  {
    "ts": null,
    "headline": "Secure by Design, Not by Chance: Sicura Introduces a New Category of Cyber Defense at InfoSec World 2025",
    "summary": "Sicura, defining the future of Security Control Management, is reinventing cybersecurity with the launch of a new software category during InfoSec World 2025. During a panel discussion featuring top security leaders from government and industry, the company will introduce Security Control Management (SCM), which offers a unified approach to risk management by operationalizing Cybersecurity and Infrastructure Security Agency (CISA) Secure By Design principles into a continuous, automated discipli",
    "url": "https://finnhub.io/api/news?id=fa41be3027bfda79d96df6370c9a303e5aa5bf911c2ce60ef9d41615b77ae0a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759233600,
      "headline": "Secure by Design, Not by Chance: Sicura Introduces a New Category of Cyber Defense at InfoSec World 2025",
      "id": 136936097,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Sicura, defining the future of Security Control Management, is reinventing cybersecurity with the launch of a new software category during InfoSec World 2025. During a panel discussion featuring top security leaders from government and industry, the company will introduce Security Control Management (SCM), which offers a unified approach to risk management by operationalizing Cybersecurity and Infrastructure Security Agency (CISA) Secure By Design principles into a continuous, automated discipli",
      "url": "https://finnhub.io/api/news?id=fa41be3027bfda79d96df6370c9a303e5aa5bf911c2ce60ef9d41615b77ae0a0"
    }
  },
  {
    "ts": null,
    "headline": "J&J gets FDA approval for Tremfya in paediatric psoriasis",
    "summary": "Tremfya is the first IL-23 inhibitor to gain FDA approval in a paediatric population.",
    "url": "https://finnhub.io/api/news?id=f5eaa8c5111905a790f503e2f341ed40d0a319b27d77f0f74a04872a54235fec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759232125,
      "headline": "J&J gets FDA approval for Tremfya in paediatric psoriasis",
      "id": 136936098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Tremfya is the first IL-23 inhibitor to gain FDA approval in a paediatric population.",
      "url": "https://finnhub.io/api/news?id=f5eaa8c5111905a790f503e2f341ed40d0a319b27d77f0f74a04872a54235fec"
    }
  },
  {
    "ts": null,
    "headline": "enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer",
    "summary": "BOSTON & MONTREAL, September 30, 2025--enGene Holdings Inc. (Nasdaq: ENGN, \"enGene\" or the \"Company\"), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025.",
    "url": "https://finnhub.io/api/news?id=b20c79603146389f7938fb528fbc7a43a2ce42ea5753e561720003c6db3375b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759231800,
      "headline": "enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer",
      "id": 136936099,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BOSTON & MONTREAL, September 30, 2025--enGene Holdings Inc. (Nasdaq: ENGN, \"enGene\" or the \"Company\"), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025.",
      "url": "https://finnhub.io/api/news?id=b20c79603146389f7938fb528fbc7a43a2ce42ea5753e561720003c6db3375b5"
    }
  },
  {
    "ts": null,
    "headline": "Genmab Strikes $8 Billion Deal for Cancer Treatment Maker Merus",
    "summary": "BMO analysts said in a note Monday they were “encouraged” that Genmab’s acquisition “could start to spur broader M&A in the sector.”",
    "url": "https://finnhub.io/api/news?id=5e6093f3a5511a13b171e615c5fa9bdd4a507ce70ae291aa8eda81457ffd1f08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759228200,
      "headline": "Genmab Strikes $8 Billion Deal for Cancer Treatment Maker Merus",
      "id": 136937616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BMO analysts said in a note Monday they were “encouraged” that Genmab’s acquisition “could start to spur broader M&A in the sector.”",
      "url": "https://finnhub.io/api/news?id=5e6093f3a5511a13b171e615c5fa9bdd4a507ce70ae291aa8eda81457ffd1f08"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) to Withdraw Acid Reflux Treatment in Some Markets",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best conservative stocks to buy now. On September 23, the company announced plans to withdraw the LINX Reflux Management System in certain countries. The company has cited commercial reasons for withdrawing the device used to treat acid reflux disease. The withdrawal follows a thorough evaluation of market […]",
    "url": "https://finnhub.io/api/news?id=e26b38c5a82b532d422a69c1035b37d64e890bc9c79d39b37e9de8ae67b4cda7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759219233,
      "headline": "Johnson & Johnson (JNJ) to Withdraw Acid Reflux Treatment in Some Markets",
      "id": 136934060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best conservative stocks to buy now. On September 23, the company announced plans to withdraw the LINX Reflux Management System in certain countries. The company has cited commercial reasons for withdrawing the device used to treat acid reflux disease. The withdrawal follows a thorough evaluation of market […]",
      "url": "https://finnhub.io/api/news?id=e26b38c5a82b532d422a69c1035b37d64e890bc9c79d39b37e9de8ae67b4cda7"
    }
  }
]